Zeravion Horizon · For pharma
Longitudinal urinary intelligence for clinical trials
Zeravion Horizon is a toilet-integrated research platform for high-frequency longitudinal urinary biomarker monitoring across routine toilet visits — with minimal patient burden.
Same trial. A completely different dataset.
- samples per patient today
- 3
- measurements with Horizon
- 1,440
- extra patient effort
- 0
Clinical trials see snapshots. Biology happens continuously.
Urinalysis is already widely used in clinical trials, but most protocols capture only occasional samples. Treatment response, toxicity signals and biological changes can emerge between visits and disappear before the next scheduled measurement.
Horizon closes that gap by turning routine toilet visits into a longitudinal biomarker timeline.
Today
Horizon
See trajectories
Not just individual values.
Capture change
Between scheduled visits.
Build longitudinal evidence
Across patients and trials.
The platform
Built to capture what happens between visits
A retrofit device integrates with existing toilets and passively captures 10 established urinary parameters during routine toilet visits.
- Passive
- No cup. No manual collection. No change to patient routine.
- Continuous
- High-frequency measurements create individual biomarker trajectories over time.
- Connected
- Data is captured optically and transferred wirelessly for integration into clinical research workflows.
Current panel
- Leukocytes
- Nitrite
- Protein
- Blood
- Glucose
- Ketones
- pH
- Specific Gravity
- Bilirubin
- Urobilinogen
Expandable to additional biomarkers based on research needs.
Research potential
What could longitudinal urinary data unlock?
Discover new signals
Reveal treatment-response, safety or disease trajectories currently missed between visits.
Better patient stratification
Explore whether longitudinal patterns can identify responder populations earlier.
Higher-quality evidence
Investigate whether denser measurement can reduce variability and strengthen evidence generation.
Earlier decisions
Explore whether emerging biomarker trends can support more confident development decisions.
The value isn't more urine tests. It's a new type of clinical dataset.
Let's find out together.
We are looking for a pharmaceutical partner to co-develop and validate the first applications of Zeravion Horizon in clinical trials. Together, we want to identify the most valuable clinical applications, generate the first longitudinal datasets and build the evidence needed to take continuous urinary intelligence into future trials.
Zeravion brings
- Longitudinal measurement platform
- Data infrastructure
- Technology development
- Regulatory development
Pharma brings
- Clinical programs
- Therapeutic expertise
- Biomarker strategy
- Clinical context
= New longitudinal clinical evidence
- Identify relevant biomarker patterns
- Develop new endpoints and algorithms
- Validate them in real clinical programs
- Generate publications and evidence
- Expand into new biomarkers and therapeutic areas
Status
Ready for the first collaboration.
Zeravion Horizon is a functional 10-parameter prototype with wireless data transfer. The platform has been internally benchmarked against a state-of-the-art reader, with validation ongoing, and is being prepared for its first pharma study and IVDR Class A registration.
Horizon is where continuous urinary intelligence begins.
The longitudinal data generated through clinical research helps build the foundation for Zeravion's larger vision: AI models that learn biological patterns, detect meaningful deviations and enable earlier prediction.